Supernus Pharmaceuticals SUPN Other Non-Current Liabilities
Other Non-Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherLiabilitiesNoncurrent.
The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Supernus Pharmaceuticals's other non-current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Supernus Pharmaceuticals's other non-current liabilities?
- Supernus Pharmaceuticals (SUPN) reported other non-current liabilities of $19.52M in Q1 2026.
- How has Supernus Pharmaceuticals's other non-current liabilities changed year-over-year?
- Supernus Pharmaceuticals's other non-current liabilities increased by 161.5% year-over-year, from $7.46M to $19.52M.
- What is the long-term trend for Supernus Pharmaceuticals's other non-current liabilities?
- Over 5 years (2020 to 2025), Supernus Pharmaceuticals's other non-current liabilities has grown at a -12.3% compound annual growth rate (CAGR), from $42.79M to $22.19M.
- What does other non-current liabilities mean?
- Miscellaneous long-term obligations not classified in specific categories — pension liabilities, environmental remediation, and other long-term accruals.